SlideShare a Scribd company logo
OVERVIEW
OF BRAIN
TUMORS
BY
DR. AYUSH GARG
ANATOMY
EPIDEMIOLOGY
It is the 20th most common malignancy worldwide and 14th most common in India according to
GLOBOCAN 2020 data.
 whites  males (except meningiomas and schwannomas) .
High mortality upto 75%
Dramatic improvement in children and young adult, mortality  by 50% between 1975 to 2010
Tumors that have a propensity for CSF spread include
◦ Medulloblastomas
◦ Germ cell tumors
◦ CNS lymphoma
Neuro Oncol, Volume 22, Issue Supplement_1, October 2020, Pages iv1–iv96, https://doi.org/10.1093/neuonc/noaa200
The content of this slide may be subject to copyright: please see the slide notes for details.
Distribution of All Primary Brain and Other CNS Tumors
(Malignant and Non-Malignant Combined)
Site Histology
CBTRUS 2020
Glioblastoma
14.5%
Pituitary
16.9%
Nerve sheath
tumor 8.6%
Meningioma 38.3%
Neuro Oncol, Volume 22, Issue Supplement_1, October 2020, Pages iv1–iv96, https://doi.org/10.1093/neuonc/noaa200
The content of this slide may be subject to copyright: please see the slide notes for details.
CBTRUS 2020
Distributionof All Primary Brain and Other CNS Gliomas
Site Histology
Out of all
gliomas
GBM: 57.7%
Neuro Oncol, Volume 22, Issue Supplement_1, October 2020, Pages iv1–iv96, https://doi.org/10.1093/neuonc/noaa200
The content of this slide may be subject to copyright: please see the slide notes for details.
CBTRUS 2020
Age adjusted incidence rates of Brain and Other CNS
Tumors
ETIOLOGY
Occupational & Environmental factors
 Prior exposure to ionizing and non-ionizing radiation (2.3% incidence of
primary brain tumors in children treated with PCI for acute leukemia, a
22 fold increase expected)
 Farmers and petrochemical workers
 Chemical exposures (formaldehyde, vinyl chloride, acrylonitrile, etc.)
 Cellular telephones ?????
Hereditary Syndromes
 Cowden,Turcot, Lynch & Li-Fraumeni (Gliomas)
 Gorlin(PNET), neurofibromatosis type I&II (meningiomas, optic nerve
glioma, shwannoma)
 VHL (haemangioblastoma)
Neuroepithelial Tumors :
Glial cell origin: Astrocytoma, Oligodendroglioma, Ependymoma, Choroid plexus
Neuronal and mixed neuro–glial origin: Gangliocytoma, Neurocytoma, Papillary
glioneuronal tumor, Rosette-forming glioneural tumor of the fourth ventricle
Embryonal Tumors : Medulloblastoma, PNET
Classification of Adult Brain
Tumors
Tumors of specialized anatomic structures:
 Pituitary Adenoma
 Craniopharyngioma
 Pineocytoma
 Chordoma
 Haemangiopericytoma
 Germ Cell Tumors
 Choroid Plexus Tumors
Classification of Adult Brain
Tumors
 Tumors of meninges (meningoepithilial cells, mesenchymal)
 Tumors of haematopoitic system
 Lymphoma
 Plasmacytoma
 Metastatic
Classification of Adult Brain
Tumors
WHO grade I = low proliferative potential, a frequently discrete nature,
and the possibility of cure following surgical resection alone.
WHO grade II = generally infiltrating and low in mitotic activity but recur
more frequently than grade I malignant tumors after local therapy. Some
tumor types tend to progress to higher grades of malignancy.
WHO grade III = anaplastic histology & infiltrative, usually treated with
aggressive adjuvant therapy.
WHO grade IV = mitotically active, necrosis-prone , micro-vascular
proliferation & generally associated with a rapid pre & post-operative
progression & fatal outcomes, usually treated with aggressive adjuvant
therapy.
Grading of Adult Brain Tumors
PATHOLOGY
Primary intracranial tumors are of ecto- and mesodermal origin and arise from the brain, cranial nerves,
meninges, pituitary, pineal, and vascular elements.
In 2016, the WHO revised its classification system for pathologic subtypes of CNS tumors to combine
histology with molecular parameters such as:
 IDH1 mutation
 1p19q codeletion for gliomas
 H3 K27M mutation
 RELA fusion for ependymoma
 WNT and SHH activation for medulloblastoma
But in 2021…..
Gliomas, glioneuronal tumors, and neuronal tumors
1) Adult-type diffuse gliomas
 Astrocytoma, IDH-mutant
 Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted
 Glioblastoma, IDH-wildtype
2) Pediatric-type diffuse low-grade gliomas
3) Pediatric-type diffuse high-grade gliomas
4) Circumscribed astrocytic gliomas
5) Glioneuronal and neuronal tumors
6) Ependymal tumors
Two major changes:
 Roman numerals have been changed to Arabic numerals (I → 1, II → 2, III →
3, IV → 4)
 Grading within tumor types
(1) to provide more flexibility in using grade relative to the tumor type
(2) to emphasize biological similarities within tumor types rather than
approximate clinical behavior
(3) to conform with WHO grading in non-CNS tumor types.
Increased
intracranial
pressure
Seizures
Physiological
deficits specific
to location
Neurocognitive
deficits
Endocrinal
dysfunction
CLINICAL PRESENTATION
SITE WISE CLINICAL PRESENTATION
Tumors Symptoms
GBM /
Astrocytoma
Headache, seizure, unilateral weakness, mental changes
Meningioma Localized Headache
Cerebral Headache, seizure, unilateral weakness, mental changes
Cerebellar Occipital Headache
Brainstem or
thalamus
Nausea, vomiting, ataxia
CLINICAL PRESENTATION
Tumors Symptoms
Optic nerve Ocular changes
Medulloblastoma Morning headaches, nausea, vomiting
Ependymoma Morning headaches, nausea, vomiting
Neurilemoma,
schwannoma,
Neurinomas
Unilateral deafness, vertigo
Craniopharyngioma Headache, mental changes, hemiplegia, seizure, vomiting, visual
impairment
CLINICAL PRESENTATION
DIAGNOSTIC WORK UP
 Complete history and physical examination
 Magnetic Resonance Imaging
 CT Scan
 Newer Imaging Modalities
 FDG PET-CT is approved in USA, FLT and F-DOPA are being evaluated
 Cerebrospinal Fluid Examination
 Medulloblastoma, ependymoma, choroid plexus carcinoma, lymphoma, and some
embryonal pineal and suprasellar region tumors have high likelihood of spreading to CSF.
 Biopsy (craniotomy / stereotactic)
 IHC & Cyto-genetics
T1WI T2WI
FLAIR
Cerebrospinal fluid Dark Bright Dark
Fat Bright Dark Bright
Solid mass (tumor) Dark Bright Bright
Edema Dark Bright Bright
Cyst Dark Bright Dark
MRI
High-grade glioma — High-grade gliomas are typically hypointense masses on T1-
weighted images that enhance heterogeneously following contrast infusion
Low-grade glioma — Low-grade gliomas in adults generally appear as T2/FLAIR
hyperintense, expansile lesions involving both cortex and underlying white matter
matter
Meningioma — On MRI, a typical meningioma is an
extra-axial, dural-based mass that is isointense or
hypointense to gray matter on T1 and isointense or
hyperintense on T2-weighted images
Brain metastases — Brain metastases typically appear as rounded, well-
circumscribed masses that enhance after administration of contrast
Biopsy
When biopsy is not indicated
 Known active systemic cancer and multiple lesions that are radiographically
consistent with brain metastases
 Brainstem glioma
 Optic nerve meningioma
 HIV positive patients with CT or MRI findings consistent with primary CNS
lymphoma (PCNSL)
 Positive Epstein-Barr virus PCR in the CSF
 Patients with secretory germ cell tumors
Common Adult Tumors Frequent Gene and Chromosomal Alterations
Astrocytoma, IDH-mutant IDH1, IDH2, ATRX, TP53, CDKN2A/B
Oligodendroglioma, IDH-mutant, and
1p/19q-codeleted
IDH1, IDH2, 1p/19q, TERT promoter, CIC, FUBP1, NOTCH1
Glioblastoma, IDH-wildtype IDH-wildtype, TERT promoter, chromosomes 7/10, EGFR
Medulloblastoma, WNT-activated CTNNB1, APC
Medulloblastoma, SHH-activated TP53, PTCH1, SUFU, SMO, MYCN, GLI2 (methylome)
Meningioma NF2, AKT1, TRAF7, SMO, PIK3CA; KLF4, SMARCE1,
BAP1 in subtypes; H3K27me3; TERT promoter, CDKN2A/B
in CNS WHO grade 3
IHC & CYTOGENETICS
IDH 1/2 Mutation 1p/19q Co-deletion MGMT promoter
methylation
Diffuse astro (GRII) 70%-80% 15% 40%-50%
Oligod/astro (GRII) 70%-80% 30%-60% 60%-80%
Astro(GR III) 50%-70% 15% 50%
Oligod/astro (GR III) 50%-80% 50%-80% 70%
GBM (GR IV) 5% - 10% <5% 35%
Diagnostic role DD glioma vs.gliosis
Typical for transformed
LGG
Pathognomonic for
oligodendroglioma
None
Prognostic role Protracted natural history
in IDH-mutated tumors
Protracted natural history
in 1p/19q codeleted
tumours
Prognostic for AG (+/-
with IDH mutations)
treated with RT / CT
Predictive role Absence of mutation
suggests predictive role
for MGMT promoter
methylation
Prolongation of survival
with early chemotherapy
in 1p/19-co-deleted OD
Predictive in GBM for benefit
from alkalating CT Elderly
GBM: MGMT-methyl = TMZ
MGMT – unmethyl=RT
MANAGEMENT
Medical management
•Increased intracranial
pressure
•Seizures
•Venous thromboembolic
disease
Surgery Radiation
Therapy
Chemotherapy
and targeted
agents
GENERAL MANAGEMENT
Cerebral Edema
Glucocorticoids are used to control neurologic signs and symptoms
Dexamethasone 2-4mg twice daily
Seizures
Anticonvulsants, such as levetiracetam, lacosamide, lamotrigine, and
pregabalin are preferred
Prophylactic anticonvulsant use (in patients who have never experienced a
seizure) remains controversial because there is lack of data.
SURGERY
Surgical Procedures
 Biopsy
 Total Resection
 Surgical Debulking
 CSF Diversion
 Re-resection
RADIATION THERAPY
Radiobiologic Considerations Underlying Tissue Injury
The process of radiation injury depends on
Technical factors: Dose, Volume, Fraction size, Specific target cell population,
Secondary mechanisms: blood vessel injury resulting in hypoxia, edema
Reactive gliosis
Host factors: Inherent Radiosensitivity of different organs within brain (Ex. Optic
chiasm, hypothalamus, Lacrimal gland, Lenses are sensitive to radiation than
others)
RADIATION THERAPY
Partial-brain irradiation, 3DCRT, IMRT, IGRT
Whole-brain radiotherapy (WBRT)
Cranio-spinal irradiation (CSI)
Stereotactic radiosurgery (SRS)
Fractionated stereotactic radiotherapy (FSRT)
Brachytherapy (less common)
Proton beam therapy (3DPT, IMPT)
CT SIMULATION ADVANTAGE : Coverage of meninges in
subfrontal region and sparing of lens in CSI.
CT SIMULATION
•Contouring of the cord and
overlying meninges that
extend laterally to the lateral
aspect of the spinal ganglia
results in a  field width than
one based on bony anatomy.
•The addition of shielding
further reduces the volume of
normal tissues included in the
treated volume.
Surgery :
Except deep seated lesions such as pontine glioma
Complete resection not achievable frequently
Radiotherapy :
RT immediately or after progression
EORTC TRIAL 22845 – 7.4 vs .7.2 yrs OS. but PFS 5.3 vs. 3.4
Conclusion in doubt
No difference in survival of dose escalation
Surveillance
General principle of treatment in
adult Low Grade Gliomas (LGG)
Risk factors for survival in Low Grade Gliomas
 Age (<40 vs, > 40 years old)
 Tumor largest diameter (<6 cm vs. > 6 cm)
 Tumor crossing midline (yes vs. no)
 HPE tumor type (oligodendroglioma or mixed vs. astrocytoma)
 Neurologic deficit present preoperatively (absent vs. present)
Survival
 Low risk (0-2) 7.8 (6.8 - 8.9) yrs.
 High risk (3-5) 3.7 (2.9 - 4.7) yrs.
General principle of treatment in
adult Low Grade Gliomas (LGG)
General principle of treatment in
adult High Grade Gliomas (HGG)
General principle of treatment in
adult High Grade Gliomas (HGG)
General principle of treatment in
adult High Grade Gliomas (HGG)
BRACHYTHERAPY
Selection criteria:
 Tumor confined to one hemisphere
 No transcallosal or subependymal spread
 Small size (<5 to 6 cm)
 Well circumscribed on CT or MRI
 Accessible location for the implant.
Procedure:
 A balloon based system, GliaSite, placed into the cavity at the time of surgery
 Balloon is filled with organically bound iodine-125 (125I)
 Treatment is completed within 3 to 7 days
 Direct infusion of radioimmunoglobulins has been used in primary and
recurrent brain gliomas
CHEMOTHERAPY AND
TARGETED AGENTS
CNS tumors are resistant to most chemotherapeutic agents as they are unable to
cross BBB.
Alkylating agents such as BCNU (carmustine) and CCNU (lomustine) cross the
BBB, but prolonged use causes myelotoxicity and pulmonary fibrosis
Procarbazine has similar efficacy but is better tolerated
Temozolomide (TMZ), has excellent bioavailability and is the only agent to
demonstrate a survival benefit for glioblastoma and anaplastic astrocytoma
Radiation therapy with immediate chemotherapy (PCV) prolongs survival in patients
with anaplastic oligodendroglioma and high-risk low-grade gliomas.
Implantation of slow-release chemotherapy wafers into a tumor resection cavity or
convection-enhanced drug (CED) delivery have been used to bypass BBB.
VEGF pathway inhibitor bevacizumab is the only targeted agent approved for GBM
Two large randomized trials of bevacizumab for the treatment of newly diagnosed GBM
improved PFS but failed to improve OS
Vaccines under development:
 Rindopepimut (EGFRvIII-targeted peptide vaccine)
 DC Vax (autologous tumor lysate-pulsed dendritic cell vaccine)
 ICT-107 (dendritic cells prepared from autologous mononuclear cells that are
pulsed with six synthetic peptides)
 HSPPC-96 (autologous tumor-derived heat shock protein [glycoprotein 96])
TOXICITY
General symptoms:
 Fatigue
 Headache
 Drowsiness
 Dermatitis
 Alopecia
 Nausea and vomiting (raised ICP, posterior fossa or brainstem irradiation)
 Otitis externa (if ear in the field)
Acute Toxicity
Transient worsening of pretreatment deficits may develop during the course of
radiotherapy, and further acute toxicities may manifest up to 6 weeks following
completion of irradiation.
These symptoms are consequence of a transient peritumoral edema and usually
respond to a short-term increase of corticosteroids
Sub Acute Toxicity
Toxicity that develops during the 6-week to 6-month period following irradiation is
is attributed to changes in capillary permeability as well as transient demyelination
demyelination due to damage to oligodendroglial cells.
Symptoms include: headache, somnolence and fatigability
Late Toxicity
Late sequelae of radiotherapy appear from 6 months to many years following
treatment and are usually irreversible and progressive
They are thought to be due to white matter damage from vascular injury,
demyelination, and necrosis
The most serious late reaction to radiotherapy is radiation necrosis, which has a
peak incidence at 3 years
FOLLOW UP
Periodic MRIs are used to detect tumor recurrence/ treatment response
Assessment of cognitive functioning and quality of life
Monitoring of for neuroendocrine and ophthalmologic side effects
Type Location Clinical F Survival RT CT
A Supratent slow growing 5 yr MS Res At recc.
AA Supratent Rapid growing 2.5 yr MS Yes Yes
GBM Supratent  Malignant 1 yr MS Yes Yes
OG Supratent  Seizures 5 yr MS Yes Yes
MN convexity  Women Long term Yes Rare
clival (Gr II& III, res Gr I)
LYMP Multifocal  CSF/ ocular 3-5 Yr MS Yes Yes
periventricular Diss.
A=Astrocytoma (adult>child), AA=Anaplastic astrocytoma, GBM=Glioblastoma (elderly), OG=Oligodendroglioma (any
age), MN= Meningioma, Res= residual, Recc= recurrence
Type Location Clinical F Survival RT CT
BSG Pons Fatal 1 Yr MS Yes Seldom
PA Cerebellum Cure with TR 80% 10 yr Res Yes
hypothalamus
EPDM 4th ventricle Cure with TR 70% 5 yr Yes# Seldom
cauda equina can diss. in CSF
MDBM Cerebellum likely to 70% - 80% Yes Yes
diss. in CSF
GERM Pineal & Sensitive to CT 80% 5Yr Yes Yes
suprasellar & RT
BSG=brain stem glioma,PA=Pilocytic astrocytoma (child>adult), EPDM=Ependymoma (child, adult), MDBM=
medulloblastoma (child>adult), GERM = Germinoma, #= Gr II & III, Res
SUMMARY
 Metastases from a systemic cancer are the most common brain tumors in
adults
 Among primary brain tumors, meningiomas and gliomas together account for
more than two-thirds of all adult primary brain tumors
 Pignatti scoring, RPA and GPA used for prognosis grading
 MRI with contrast is the optimal study for evaluation of brain tumors
 Histopathology is gold standard for final diagnosis until or unless eloquent
area
SUMMARY
 Molecular markers important aspect of diagnosis
 Glucocorticoids are used to decrease peritumoral edema and elevated ICP
 Conformal radiotherapy better spares OAR as compared to conventional
techniques
 Hippocampal avoidance may improve neurocognitive function
Your best quote that reflects your
approach… “It’s one small step for
man, one giant leap for mankind.”
- NEIL ARMSTRONG

More Related Content

What's hot

Meningioma of brain
Meningioma of brainMeningioma of brain
Meningioma of brain
suresh Bishokarma
 
WHO BRAIN TUMOR CLASSIFICATION 5th EDITION
WHO BRAIN TUMOR CLASSIFICATION 5th EDITIONWHO BRAIN TUMOR CLASSIFICATION 5th EDITION
WHO BRAIN TUMOR CLASSIFICATION 5th EDITION
Kanhu Charan
 
Meningioma and ependymoma.
Meningioma and ependymoma.Meningioma and ependymoma.
Meningioma and ependymoma.
Kiran Ramakrishna
 
Low Grade Gliomas
Low  Grade  GliomasLow  Grade  Gliomas
Low Grade Gliomas
Arnab Bose
 
Pineal gland tumors
Pineal gland tumorsPineal gland tumors
Pineal gland tumors
airwave12
 
Radiation for Glioblastoma
Radiation for GlioblastomaRadiation for Glioblastoma
Radiation for Glioblastoma
Robert J Miller MD
 
Medulloblastoma
MedulloblastomaMedulloblastoma
Medulloblastoma
MedulloblastomaMedulloblastoma
Medulloblastoma
DrAyush Garg
 
Recent updates in cns tumors
Recent updates in cns tumorsRecent updates in cns tumors
Recent updates in cns tumors
dhanya89
 
Glioblastoma Multiforme.Dr NG NeuroEdu
Glioblastoma Multiforme.Dr NG NeuroEduGlioblastoma Multiforme.Dr NG NeuroEdu
Glioblastoma Multiforme.Dr NG NeuroEduslneurosurgery
 
Brain metastasis - Simplified
Brain metastasis - SimplifiedBrain metastasis - Simplified
Brain metastasis - Simplified
suresh Bishokarma
 
Meningioma
MeningiomaMeningioma
Meningioma
Adam Chen
 
Cancer of unknown primary: Knowing the unknown
Cancer of unknown primary: Knowing the unknownCancer of unknown primary: Knowing the unknown
Cancer of unknown primary: Knowing the unknown
Mary Ondinee Manalo Igot
 
Newly Diagnosed Glioblastoma Multiforme: Recent updates; evidence-based medic...
Newly Diagnosed Glioblastoma Multiforme: Recent updates; evidence-based medic...Newly Diagnosed Glioblastoma Multiforme: Recent updates; evidence-based medic...
Newly Diagnosed Glioblastoma Multiforme: Recent updates; evidence-based medic...
Osama Elzaafarany, MD.
 
Pathology of CNS Tumors
Pathology of CNS TumorsPathology of CNS Tumors
Pathology of CNS Tumors
Shashidhar Venkatesh Murthy
 
MANAGEMENT OF PITUITARY TUMORS.pptx
MANAGEMENT OF PITUITARY  TUMORS.pptxMANAGEMENT OF PITUITARY  TUMORS.pptx
MANAGEMENT OF PITUITARY TUMORS.pptx
Kiran Ramakrishna
 
High Grade Glioma
High Grade GliomaHigh Grade Glioma
High Grade Glioma
DrAyush Garg
 
Brain tumor
Brain tumor Brain tumor
Brain tumor
NeurologyKota
 

What's hot (20)

Meningioma of brain
Meningioma of brainMeningioma of brain
Meningioma of brain
 
WHO BRAIN TUMOR CLASSIFICATION 5th EDITION
WHO BRAIN TUMOR CLASSIFICATION 5th EDITIONWHO BRAIN TUMOR CLASSIFICATION 5th EDITION
WHO BRAIN TUMOR CLASSIFICATION 5th EDITION
 
Cns tumors
Cns tumorsCns tumors
Cns tumors
 
Meningioma and ependymoma.
Meningioma and ependymoma.Meningioma and ependymoma.
Meningioma and ependymoma.
 
Low Grade Gliomas
Low  Grade  GliomasLow  Grade  Gliomas
Low Grade Gliomas
 
Pineal gland tumors
Pineal gland tumorsPineal gland tumors
Pineal gland tumors
 
Radiation for Glioblastoma
Radiation for GlioblastomaRadiation for Glioblastoma
Radiation for Glioblastoma
 
Medulloblastoma
MedulloblastomaMedulloblastoma
Medulloblastoma
 
Medulloblastoma
MedulloblastomaMedulloblastoma
Medulloblastoma
 
Recent updates in cns tumors
Recent updates in cns tumorsRecent updates in cns tumors
Recent updates in cns tumors
 
Glioblastoma Multiforme.Dr NG NeuroEdu
Glioblastoma Multiforme.Dr NG NeuroEduGlioblastoma Multiforme.Dr NG NeuroEdu
Glioblastoma Multiforme.Dr NG NeuroEdu
 
Glioblastoma Multiforme
Glioblastoma MultiformeGlioblastoma Multiforme
Glioblastoma Multiforme
 
Brain metastasis - Simplified
Brain metastasis - SimplifiedBrain metastasis - Simplified
Brain metastasis - Simplified
 
Meningioma
MeningiomaMeningioma
Meningioma
 
Cancer of unknown primary: Knowing the unknown
Cancer of unknown primary: Knowing the unknownCancer of unknown primary: Knowing the unknown
Cancer of unknown primary: Knowing the unknown
 
Newly Diagnosed Glioblastoma Multiforme: Recent updates; evidence-based medic...
Newly Diagnosed Glioblastoma Multiforme: Recent updates; evidence-based medic...Newly Diagnosed Glioblastoma Multiforme: Recent updates; evidence-based medic...
Newly Diagnosed Glioblastoma Multiforme: Recent updates; evidence-based medic...
 
Pathology of CNS Tumors
Pathology of CNS TumorsPathology of CNS Tumors
Pathology of CNS Tumors
 
MANAGEMENT OF PITUITARY TUMORS.pptx
MANAGEMENT OF PITUITARY  TUMORS.pptxMANAGEMENT OF PITUITARY  TUMORS.pptx
MANAGEMENT OF PITUITARY TUMORS.pptx
 
High Grade Glioma
High Grade GliomaHigh Grade Glioma
High Grade Glioma
 
Brain tumor
Brain tumor Brain tumor
Brain tumor
 

Similar to Overview of brain tumors

Management of gliomas
Management of gliomasManagement of gliomas
Management of gliomas
Jasmeet Tuteja
 
Who intracranial tumour classification 2016 update- Dr S. Kiranmai
Who intracranial tumour classification 2016 update- Dr S. KiranmaiWho intracranial tumour classification 2016 update- Dr S. Kiranmai
Who intracranial tumour classification 2016 update- Dr S. Kiranmai
benedictsyndrome
 
Cns tumors
Cns tumorsCns tumors
Cns tumors
test
 
Brain tumors 2020 by Assist.Prof. Ines Strenja MD, PhD Clinical hospital R...
Brain tumors  2020 by Assist.Prof. Ines Strenja  MD, PhD  Clinical hospital R...Brain tumors  2020 by Assist.Prof. Ines Strenja  MD, PhD  Clinical hospital R...
Brain tumors 2020 by Assist.Prof. Ines Strenja MD, PhD Clinical hospital R...
Neurology Dpt, Clinical Hospital Rijeka
 
LOW GRADE GLIOMA.pptx
LOW GRADE GLIOMA.pptxLOW GRADE GLIOMA.pptx
LOW GRADE GLIOMA.pptx
Brijesh Maheshwari
 
low grade glioma.pptx
low grade glioma.pptxlow grade glioma.pptx
low grade glioma.pptx
MedhatMoustafa3
 
Giant Glioblastoma in a Patient with Previous Prostate Adenocarcinoma_Crimson...
Giant Glioblastoma in a Patient with Previous Prostate Adenocarcinoma_Crimson...Giant Glioblastoma in a Patient with Previous Prostate Adenocarcinoma_Crimson...
Giant Glioblastoma in a Patient with Previous Prostate Adenocarcinoma_Crimson...
CrimsonPublishersAICS
 
Evolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumorsEvolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumors
Anil Gupta
 
Brain tumor dr. abeer elsayed
Brain tumor dr. abeer elsayedBrain tumor dr. abeer elsayed
Brain tumor dr. abeer elsayed
Abeer Ibrahim
 
CNS tumors and Neuroblastomas
CNS tumors and NeuroblastomasCNS tumors and Neuroblastomas
CNS tumors and NeuroblastomasSariu Ali
 
Central nervous system 3
Central nervous system 3Central nervous system 3
Central nervous system 3
Dr. Arpit Gohel
 
PRIMARY TUMOUR OF CNS IN ADLUT.pptx
PRIMARY TUMOUR OF CNS IN ADLUT.pptxPRIMARY TUMOUR OF CNS IN ADLUT.pptx
PRIMARY TUMOUR OF CNS IN ADLUT.pptx
NeurologyKota
 
PRIMARY TUMOUR OF CNS IN ADULT
PRIMARY TUMOUR OF CNS IN ADULTPRIMARY TUMOUR OF CNS IN ADULT
PRIMARY TUMOUR OF CNS IN ADULT
NeurologyKota
 
Glioblastoma multiforme
Glioblastoma multiformeGlioblastoma multiforme
Glioblastoma multiforme
عبد الحافظ الحميري
 
Brain tumors Imaging
Brain tumors Imaging Brain tumors Imaging
Brain tumors Imaging
MiadAlsulami
 
Primary brain tumors in adults
Primary brain tumors in adultsPrimary brain tumors in adults
Primary brain tumors in adults
Maria Barreto
 
Cellular pathology of cns.pptx
Cellular pathology of cns.pptxCellular pathology of cns.pptx
Cellular pathology of cns.pptx
SafuraIjaz
 
Glioblastoma Multiforme
Glioblastoma MultiformeGlioblastoma Multiforme
Glioblastoma Multiforme
Atheer Al-zubedi
 
high grade glioma.pptx
high grade glioma.pptxhigh grade glioma.pptx
high grade glioma.pptx
MedhatMoustafa3
 

Similar to Overview of brain tumors (20)

Management of gliomas
Management of gliomasManagement of gliomas
Management of gliomas
 
Who intracranial tumour classification 2016 update- Dr S. Kiranmai
Who intracranial tumour classification 2016 update- Dr S. KiranmaiWho intracranial tumour classification 2016 update- Dr S. Kiranmai
Who intracranial tumour classification 2016 update- Dr S. Kiranmai
 
Cns tumors
Cns tumorsCns tumors
Cns tumors
 
Brain tumors 2020 by Assist.Prof. Ines Strenja MD, PhD Clinical hospital R...
Brain tumors  2020 by Assist.Prof. Ines Strenja  MD, PhD  Clinical hospital R...Brain tumors  2020 by Assist.Prof. Ines Strenja  MD, PhD  Clinical hospital R...
Brain tumors 2020 by Assist.Prof. Ines Strenja MD, PhD Clinical hospital R...
 
LOW GRADE GLIOMA.pptx
LOW GRADE GLIOMA.pptxLOW GRADE GLIOMA.pptx
LOW GRADE GLIOMA.pptx
 
A Case of CNS Tumour
A Case of CNS TumourA Case of CNS Tumour
A Case of CNS Tumour
 
low grade glioma.pptx
low grade glioma.pptxlow grade glioma.pptx
low grade glioma.pptx
 
Giant Glioblastoma in a Patient with Previous Prostate Adenocarcinoma_Crimson...
Giant Glioblastoma in a Patient with Previous Prostate Adenocarcinoma_Crimson...Giant Glioblastoma in a Patient with Previous Prostate Adenocarcinoma_Crimson...
Giant Glioblastoma in a Patient with Previous Prostate Adenocarcinoma_Crimson...
 
Evolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumorsEvolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumors
 
Brain tumor dr. abeer elsayed
Brain tumor dr. abeer elsayedBrain tumor dr. abeer elsayed
Brain tumor dr. abeer elsayed
 
CNS tumors and Neuroblastomas
CNS tumors and NeuroblastomasCNS tumors and Neuroblastomas
CNS tumors and Neuroblastomas
 
Central nervous system 3
Central nervous system 3Central nervous system 3
Central nervous system 3
 
PRIMARY TUMOUR OF CNS IN ADLUT.pptx
PRIMARY TUMOUR OF CNS IN ADLUT.pptxPRIMARY TUMOUR OF CNS IN ADLUT.pptx
PRIMARY TUMOUR OF CNS IN ADLUT.pptx
 
PRIMARY TUMOUR OF CNS IN ADULT
PRIMARY TUMOUR OF CNS IN ADULTPRIMARY TUMOUR OF CNS IN ADULT
PRIMARY TUMOUR OF CNS IN ADULT
 
Glioblastoma multiforme
Glioblastoma multiformeGlioblastoma multiforme
Glioblastoma multiforme
 
Brain tumors Imaging
Brain tumors Imaging Brain tumors Imaging
Brain tumors Imaging
 
Primary brain tumors in adults
Primary brain tumors in adultsPrimary brain tumors in adults
Primary brain tumors in adults
 
Cellular pathology of cns.pptx
Cellular pathology of cns.pptxCellular pathology of cns.pptx
Cellular pathology of cns.pptx
 
Glioblastoma Multiforme
Glioblastoma MultiformeGlioblastoma Multiforme
Glioblastoma Multiforme
 
high grade glioma.pptx
high grade glioma.pptxhigh grade glioma.pptx
high grade glioma.pptx
 

More from DrAyush Garg

Overview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and GeneticsOverview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and Genetics
DrAyush Garg
 
OSTEOSARCOMA
OSTEOSARCOMAOSTEOSARCOMA
OSTEOSARCOMA
DrAyush Garg
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancer
DrAyush Garg
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
DrAyush Garg
 
Ear carcinoma
Ear carcinomaEar carcinoma
Ear carcinoma
DrAyush Garg
 
Role of palliative care in oncology
Role of palliative care in oncologyRole of palliative care in oncology
Role of palliative care in oncology
DrAyush Garg
 
Breast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counsellingBreast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counselling
DrAyush Garg
 
Role of SBRT in lung cancer
Role of SBRT in lung cancerRole of SBRT in lung cancer
Role of SBRT in lung cancer
DrAyush Garg
 
Role of hpv in head and neck tumors
Role of hpv in head and neck tumorsRole of hpv in head and neck tumors
Role of hpv in head and neck tumors
DrAyush Garg
 
Carcinoma esophagus
Carcinoma esophagusCarcinoma esophagus
Carcinoma esophagus
DrAyush Garg
 
Cancer vaccines final
Cancer vaccines finalCancer vaccines final
Cancer vaccines final
DrAyush Garg
 
EXTRANODAL EXTENSION
EXTRANODAL EXTENSIONEXTRANODAL EXTENSION
EXTRANODAL EXTENSION
DrAyush Garg
 
Management of ca prostate
Management of ca prostateManagement of ca prostate
Management of ca prostate
DrAyush Garg
 
Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma Prostate
DrAyush Garg
 
Prognostic index in brain metastasis
Prognostic index in brain metastasisPrognostic index in brain metastasis
Prognostic index in brain metastasis
DrAyush Garg
 
Supportive care and quality of life
Supportive care and quality of lifeSupportive care and quality of life
Supportive care and quality of life
DrAyush Garg
 
Palliation brain, spinal and bone mets
Palliation brain, spinal and bone metsPalliation brain, spinal and bone mets
Palliation brain, spinal and bone mets
DrAyush Garg
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
DrAyush Garg
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
DrAyush Garg
 
LOCALLY ADVANCED BREAST CANCER
LOCALLY ADVANCED BREAST CANCERLOCALLY ADVANCED BREAST CANCER
LOCALLY ADVANCED BREAST CANCER
DrAyush Garg
 

More from DrAyush Garg (20)

Overview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and GeneticsOverview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and Genetics
 
OSTEOSARCOMA
OSTEOSARCOMAOSTEOSARCOMA
OSTEOSARCOMA
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancer
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Ear carcinoma
Ear carcinomaEar carcinoma
Ear carcinoma
 
Role of palliative care in oncology
Role of palliative care in oncologyRole of palliative care in oncology
Role of palliative care in oncology
 
Breast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counsellingBreast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counselling
 
Role of SBRT in lung cancer
Role of SBRT in lung cancerRole of SBRT in lung cancer
Role of SBRT in lung cancer
 
Role of hpv in head and neck tumors
Role of hpv in head and neck tumorsRole of hpv in head and neck tumors
Role of hpv in head and neck tumors
 
Carcinoma esophagus
Carcinoma esophagusCarcinoma esophagus
Carcinoma esophagus
 
Cancer vaccines final
Cancer vaccines finalCancer vaccines final
Cancer vaccines final
 
EXTRANODAL EXTENSION
EXTRANODAL EXTENSIONEXTRANODAL EXTENSION
EXTRANODAL EXTENSION
 
Management of ca prostate
Management of ca prostateManagement of ca prostate
Management of ca prostate
 
Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma Prostate
 
Prognostic index in brain metastasis
Prognostic index in brain metastasisPrognostic index in brain metastasis
Prognostic index in brain metastasis
 
Supportive care and quality of life
Supportive care and quality of lifeSupportive care and quality of life
Supportive care and quality of life
 
Palliation brain, spinal and bone mets
Palliation brain, spinal and bone metsPalliation brain, spinal and bone mets
Palliation brain, spinal and bone mets
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 
LOCALLY ADVANCED BREAST CANCER
LOCALLY ADVANCED BREAST CANCERLOCALLY ADVANCED BREAST CANCER
LOCALLY ADVANCED BREAST CANCER
 

Recently uploaded

How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 

Recently uploaded (20)

How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 

Overview of brain tumors

  • 3.
  • 4. EPIDEMIOLOGY It is the 20th most common malignancy worldwide and 14th most common in India according to GLOBOCAN 2020 data.  whites  males (except meningiomas and schwannomas) . High mortality upto 75% Dramatic improvement in children and young adult, mortality  by 50% between 1975 to 2010 Tumors that have a propensity for CSF spread include ◦ Medulloblastomas ◦ Germ cell tumors ◦ CNS lymphoma
  • 5. Neuro Oncol, Volume 22, Issue Supplement_1, October 2020, Pages iv1–iv96, https://doi.org/10.1093/neuonc/noaa200 The content of this slide may be subject to copyright: please see the slide notes for details. Distribution of All Primary Brain and Other CNS Tumors (Malignant and Non-Malignant Combined) Site Histology CBTRUS 2020 Glioblastoma 14.5% Pituitary 16.9% Nerve sheath tumor 8.6% Meningioma 38.3%
  • 6. Neuro Oncol, Volume 22, Issue Supplement_1, October 2020, Pages iv1–iv96, https://doi.org/10.1093/neuonc/noaa200 The content of this slide may be subject to copyright: please see the slide notes for details. CBTRUS 2020 Distributionof All Primary Brain and Other CNS Gliomas Site Histology Out of all gliomas GBM: 57.7%
  • 7. Neuro Oncol, Volume 22, Issue Supplement_1, October 2020, Pages iv1–iv96, https://doi.org/10.1093/neuonc/noaa200 The content of this slide may be subject to copyright: please see the slide notes for details. CBTRUS 2020 Age adjusted incidence rates of Brain and Other CNS Tumors
  • 8. ETIOLOGY Occupational & Environmental factors  Prior exposure to ionizing and non-ionizing radiation (2.3% incidence of primary brain tumors in children treated with PCI for acute leukemia, a 22 fold increase expected)  Farmers and petrochemical workers  Chemical exposures (formaldehyde, vinyl chloride, acrylonitrile, etc.)  Cellular telephones ????? Hereditary Syndromes  Cowden,Turcot, Lynch & Li-Fraumeni (Gliomas)  Gorlin(PNET), neurofibromatosis type I&II (meningiomas, optic nerve glioma, shwannoma)  VHL (haemangioblastoma)
  • 9. Neuroepithelial Tumors : Glial cell origin: Astrocytoma, Oligodendroglioma, Ependymoma, Choroid plexus Neuronal and mixed neuro–glial origin: Gangliocytoma, Neurocytoma, Papillary glioneuronal tumor, Rosette-forming glioneural tumor of the fourth ventricle Embryonal Tumors : Medulloblastoma, PNET Classification of Adult Brain Tumors
  • 10. Tumors of specialized anatomic structures:  Pituitary Adenoma  Craniopharyngioma  Pineocytoma  Chordoma  Haemangiopericytoma  Germ Cell Tumors  Choroid Plexus Tumors Classification of Adult Brain Tumors
  • 11.  Tumors of meninges (meningoepithilial cells, mesenchymal)  Tumors of haematopoitic system  Lymphoma  Plasmacytoma  Metastatic Classification of Adult Brain Tumors
  • 12. WHO grade I = low proliferative potential, a frequently discrete nature, and the possibility of cure following surgical resection alone. WHO grade II = generally infiltrating and low in mitotic activity but recur more frequently than grade I malignant tumors after local therapy. Some tumor types tend to progress to higher grades of malignancy. WHO grade III = anaplastic histology & infiltrative, usually treated with aggressive adjuvant therapy. WHO grade IV = mitotically active, necrosis-prone , micro-vascular proliferation & generally associated with a rapid pre & post-operative progression & fatal outcomes, usually treated with aggressive adjuvant therapy. Grading of Adult Brain Tumors
  • 13. PATHOLOGY Primary intracranial tumors are of ecto- and mesodermal origin and arise from the brain, cranial nerves, meninges, pituitary, pineal, and vascular elements. In 2016, the WHO revised its classification system for pathologic subtypes of CNS tumors to combine histology with molecular parameters such as:  IDH1 mutation  1p19q codeletion for gliomas  H3 K27M mutation  RELA fusion for ependymoma  WNT and SHH activation for medulloblastoma
  • 15. Gliomas, glioneuronal tumors, and neuronal tumors 1) Adult-type diffuse gliomas  Astrocytoma, IDH-mutant  Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted  Glioblastoma, IDH-wildtype 2) Pediatric-type diffuse low-grade gliomas 3) Pediatric-type diffuse high-grade gliomas 4) Circumscribed astrocytic gliomas 5) Glioneuronal and neuronal tumors 6) Ependymal tumors
  • 16. Two major changes:  Roman numerals have been changed to Arabic numerals (I → 1, II → 2, III → 3, IV → 4)  Grading within tumor types (1) to provide more flexibility in using grade relative to the tumor type (2) to emphasize biological similarities within tumor types rather than approximate clinical behavior (3) to conform with WHO grading in non-CNS tumor types.
  • 18. SITE WISE CLINICAL PRESENTATION Tumors Symptoms GBM / Astrocytoma Headache, seizure, unilateral weakness, mental changes Meningioma Localized Headache Cerebral Headache, seizure, unilateral weakness, mental changes Cerebellar Occipital Headache Brainstem or thalamus Nausea, vomiting, ataxia
  • 19. CLINICAL PRESENTATION Tumors Symptoms Optic nerve Ocular changes Medulloblastoma Morning headaches, nausea, vomiting Ependymoma Morning headaches, nausea, vomiting Neurilemoma, schwannoma, Neurinomas Unilateral deafness, vertigo Craniopharyngioma Headache, mental changes, hemiplegia, seizure, vomiting, visual impairment CLINICAL PRESENTATION
  • 20. DIAGNOSTIC WORK UP  Complete history and physical examination  Magnetic Resonance Imaging  CT Scan  Newer Imaging Modalities  FDG PET-CT is approved in USA, FLT and F-DOPA are being evaluated  Cerebrospinal Fluid Examination  Medulloblastoma, ependymoma, choroid plexus carcinoma, lymphoma, and some embryonal pineal and suprasellar region tumors have high likelihood of spreading to CSF.  Biopsy (craniotomy / stereotactic)  IHC & Cyto-genetics
  • 21. T1WI T2WI FLAIR Cerebrospinal fluid Dark Bright Dark Fat Bright Dark Bright Solid mass (tumor) Dark Bright Bright Edema Dark Bright Bright Cyst Dark Bright Dark MRI
  • 22. High-grade glioma — High-grade gliomas are typically hypointense masses on T1- weighted images that enhance heterogeneously following contrast infusion
  • 23. Low-grade glioma — Low-grade gliomas in adults generally appear as T2/FLAIR hyperintense, expansile lesions involving both cortex and underlying white matter matter
  • 24. Meningioma — On MRI, a typical meningioma is an extra-axial, dural-based mass that is isointense or hypointense to gray matter on T1 and isointense or hyperintense on T2-weighted images
  • 25. Brain metastases — Brain metastases typically appear as rounded, well- circumscribed masses that enhance after administration of contrast
  • 26. Biopsy When biopsy is not indicated  Known active systemic cancer and multiple lesions that are radiographically consistent with brain metastases  Brainstem glioma  Optic nerve meningioma  HIV positive patients with CT or MRI findings consistent with primary CNS lymphoma (PCNSL)  Positive Epstein-Barr virus PCR in the CSF  Patients with secretory germ cell tumors
  • 27. Common Adult Tumors Frequent Gene and Chromosomal Alterations Astrocytoma, IDH-mutant IDH1, IDH2, ATRX, TP53, CDKN2A/B Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted IDH1, IDH2, 1p/19q, TERT promoter, CIC, FUBP1, NOTCH1 Glioblastoma, IDH-wildtype IDH-wildtype, TERT promoter, chromosomes 7/10, EGFR Medulloblastoma, WNT-activated CTNNB1, APC Medulloblastoma, SHH-activated TP53, PTCH1, SUFU, SMO, MYCN, GLI2 (methylome) Meningioma NF2, AKT1, TRAF7, SMO, PIK3CA; KLF4, SMARCE1, BAP1 in subtypes; H3K27me3; TERT promoter, CDKN2A/B in CNS WHO grade 3 IHC & CYTOGENETICS
  • 28. IDH 1/2 Mutation 1p/19q Co-deletion MGMT promoter methylation Diffuse astro (GRII) 70%-80% 15% 40%-50% Oligod/astro (GRII) 70%-80% 30%-60% 60%-80% Astro(GR III) 50%-70% 15% 50% Oligod/astro (GR III) 50%-80% 50%-80% 70% GBM (GR IV) 5% - 10% <5% 35% Diagnostic role DD glioma vs.gliosis Typical for transformed LGG Pathognomonic for oligodendroglioma None Prognostic role Protracted natural history in IDH-mutated tumors Protracted natural history in 1p/19q codeleted tumours Prognostic for AG (+/- with IDH mutations) treated with RT / CT Predictive role Absence of mutation suggests predictive role for MGMT promoter methylation Prolongation of survival with early chemotherapy in 1p/19-co-deleted OD Predictive in GBM for benefit from alkalating CT Elderly GBM: MGMT-methyl = TMZ MGMT – unmethyl=RT
  • 29. MANAGEMENT Medical management •Increased intracranial pressure •Seizures •Venous thromboembolic disease Surgery Radiation Therapy Chemotherapy and targeted agents
  • 30. GENERAL MANAGEMENT Cerebral Edema Glucocorticoids are used to control neurologic signs and symptoms Dexamethasone 2-4mg twice daily Seizures Anticonvulsants, such as levetiracetam, lacosamide, lamotrigine, and pregabalin are preferred Prophylactic anticonvulsant use (in patients who have never experienced a seizure) remains controversial because there is lack of data.
  • 31. SURGERY Surgical Procedures  Biopsy  Total Resection  Surgical Debulking  CSF Diversion  Re-resection
  • 32. RADIATION THERAPY Radiobiologic Considerations Underlying Tissue Injury The process of radiation injury depends on Technical factors: Dose, Volume, Fraction size, Specific target cell population, Secondary mechanisms: blood vessel injury resulting in hypoxia, edema Reactive gliosis Host factors: Inherent Radiosensitivity of different organs within brain (Ex. Optic chiasm, hypothalamus, Lacrimal gland, Lenses are sensitive to radiation than others)
  • 33. RADIATION THERAPY Partial-brain irradiation, 3DCRT, IMRT, IGRT Whole-brain radiotherapy (WBRT) Cranio-spinal irradiation (CSI) Stereotactic radiosurgery (SRS) Fractionated stereotactic radiotherapy (FSRT) Brachytherapy (less common) Proton beam therapy (3DPT, IMPT)
  • 34. CT SIMULATION ADVANTAGE : Coverage of meninges in subfrontal region and sparing of lens in CSI.
  • 35. CT SIMULATION •Contouring of the cord and overlying meninges that extend laterally to the lateral aspect of the spinal ganglia results in a  field width than one based on bony anatomy. •The addition of shielding further reduces the volume of normal tissues included in the treated volume.
  • 36.
  • 37.
  • 38. Surgery : Except deep seated lesions such as pontine glioma Complete resection not achievable frequently Radiotherapy : RT immediately or after progression EORTC TRIAL 22845 – 7.4 vs .7.2 yrs OS. but PFS 5.3 vs. 3.4 Conclusion in doubt No difference in survival of dose escalation Surveillance General principle of treatment in adult Low Grade Gliomas (LGG)
  • 39. Risk factors for survival in Low Grade Gliomas  Age (<40 vs, > 40 years old)  Tumor largest diameter (<6 cm vs. > 6 cm)  Tumor crossing midline (yes vs. no)  HPE tumor type (oligodendroglioma or mixed vs. astrocytoma)  Neurologic deficit present preoperatively (absent vs. present) Survival  Low risk (0-2) 7.8 (6.8 - 8.9) yrs.  High risk (3-5) 3.7 (2.9 - 4.7) yrs. General principle of treatment in adult Low Grade Gliomas (LGG)
  • 40. General principle of treatment in adult High Grade Gliomas (HGG)
  • 41. General principle of treatment in adult High Grade Gliomas (HGG)
  • 42. General principle of treatment in adult High Grade Gliomas (HGG)
  • 43. BRACHYTHERAPY Selection criteria:  Tumor confined to one hemisphere  No transcallosal or subependymal spread  Small size (<5 to 6 cm)  Well circumscribed on CT or MRI  Accessible location for the implant.
  • 44. Procedure:  A balloon based system, GliaSite, placed into the cavity at the time of surgery  Balloon is filled with organically bound iodine-125 (125I)  Treatment is completed within 3 to 7 days  Direct infusion of radioimmunoglobulins has been used in primary and recurrent brain gliomas
  • 45. CHEMOTHERAPY AND TARGETED AGENTS CNS tumors are resistant to most chemotherapeutic agents as they are unable to cross BBB. Alkylating agents such as BCNU (carmustine) and CCNU (lomustine) cross the BBB, but prolonged use causes myelotoxicity and pulmonary fibrosis Procarbazine has similar efficacy but is better tolerated Temozolomide (TMZ), has excellent bioavailability and is the only agent to demonstrate a survival benefit for glioblastoma and anaplastic astrocytoma
  • 46. Radiation therapy with immediate chemotherapy (PCV) prolongs survival in patients with anaplastic oligodendroglioma and high-risk low-grade gliomas. Implantation of slow-release chemotherapy wafers into a tumor resection cavity or convection-enhanced drug (CED) delivery have been used to bypass BBB. VEGF pathway inhibitor bevacizumab is the only targeted agent approved for GBM Two large randomized trials of bevacizumab for the treatment of newly diagnosed GBM improved PFS but failed to improve OS
  • 47. Vaccines under development:  Rindopepimut (EGFRvIII-targeted peptide vaccine)  DC Vax (autologous tumor lysate-pulsed dendritic cell vaccine)  ICT-107 (dendritic cells prepared from autologous mononuclear cells that are pulsed with six synthetic peptides)  HSPPC-96 (autologous tumor-derived heat shock protein [glycoprotein 96])
  • 48. TOXICITY General symptoms:  Fatigue  Headache  Drowsiness  Dermatitis  Alopecia  Nausea and vomiting (raised ICP, posterior fossa or brainstem irradiation)  Otitis externa (if ear in the field)
  • 49. Acute Toxicity Transient worsening of pretreatment deficits may develop during the course of radiotherapy, and further acute toxicities may manifest up to 6 weeks following completion of irradiation. These symptoms are consequence of a transient peritumoral edema and usually respond to a short-term increase of corticosteroids
  • 50. Sub Acute Toxicity Toxicity that develops during the 6-week to 6-month period following irradiation is is attributed to changes in capillary permeability as well as transient demyelination demyelination due to damage to oligodendroglial cells. Symptoms include: headache, somnolence and fatigability
  • 51. Late Toxicity Late sequelae of radiotherapy appear from 6 months to many years following treatment and are usually irreversible and progressive They are thought to be due to white matter damage from vascular injury, demyelination, and necrosis The most serious late reaction to radiotherapy is radiation necrosis, which has a peak incidence at 3 years
  • 52. FOLLOW UP Periodic MRIs are used to detect tumor recurrence/ treatment response Assessment of cognitive functioning and quality of life Monitoring of for neuroendocrine and ophthalmologic side effects
  • 53. Type Location Clinical F Survival RT CT A Supratent slow growing 5 yr MS Res At recc. AA Supratent Rapid growing 2.5 yr MS Yes Yes GBM Supratent  Malignant 1 yr MS Yes Yes OG Supratent  Seizures 5 yr MS Yes Yes MN convexity  Women Long term Yes Rare clival (Gr II& III, res Gr I) LYMP Multifocal  CSF/ ocular 3-5 Yr MS Yes Yes periventricular Diss. A=Astrocytoma (adult>child), AA=Anaplastic astrocytoma, GBM=Glioblastoma (elderly), OG=Oligodendroglioma (any age), MN= Meningioma, Res= residual, Recc= recurrence
  • 54. Type Location Clinical F Survival RT CT BSG Pons Fatal 1 Yr MS Yes Seldom PA Cerebellum Cure with TR 80% 10 yr Res Yes hypothalamus EPDM 4th ventricle Cure with TR 70% 5 yr Yes# Seldom cauda equina can diss. in CSF MDBM Cerebellum likely to 70% - 80% Yes Yes diss. in CSF GERM Pineal & Sensitive to CT 80% 5Yr Yes Yes suprasellar & RT BSG=brain stem glioma,PA=Pilocytic astrocytoma (child>adult), EPDM=Ependymoma (child, adult), MDBM= medulloblastoma (child>adult), GERM = Germinoma, #= Gr II & III, Res
  • 55. SUMMARY  Metastases from a systemic cancer are the most common brain tumors in adults  Among primary brain tumors, meningiomas and gliomas together account for more than two-thirds of all adult primary brain tumors  Pignatti scoring, RPA and GPA used for prognosis grading  MRI with contrast is the optimal study for evaluation of brain tumors  Histopathology is gold standard for final diagnosis until or unless eloquent area
  • 56. SUMMARY  Molecular markers important aspect of diagnosis  Glucocorticoids are used to decrease peritumoral edema and elevated ICP  Conformal radiotherapy better spares OAR as compared to conventional techniques  Hippocampal avoidance may improve neurocognitive function
  • 57. Your best quote that reflects your approach… “It’s one small step for man, one giant leap for mankind.” - NEIL ARMSTRONG

Editor's Notes

  1. Falx cerebri divides right and left cerebrum Falx cerebelli divides cerebrum with cerebellum and brainstem
  2. Fig. 6 Distributiona of All Primary Brain and Other CNS Tumors (Malignant and Non-Malignant Combined; Five-Year Total=415,411; Annual Average Cases=83,082), by A) Site and B) Histology, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2013-2017 Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.comThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
  3. Fig. 9 Distributiona of Primary Brain and Other CNS Gliomasb (Five-Year Total=104,103; Annual Average Cases=20,821) by A) Site and B) Histology Subtypes, CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2013-2017 Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.comThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
  4. Fig. 11 Age-Adjusted Incidence Ratesa of Brain and Other CNS Tumors by Selected Histologies and Age Group a) Age 0-19 Yearsb, B) Age 20+ Yearsb and CBTRUS Statistical Report: US Cancer Statistics - NPCR and SEER, 2013-2017 Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.comThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
  5. Surgical procedures can be summarized as biopsy for diagnosis only, resection for cure, surgical debulking for management of mass effect-related symptoms, CSF diversion procedures to relieve acute symptoms caused by increased intracranial pressure or hydrocephalus, and increasingly re-resection to distinguish and manage the effects of progressive tumor from symptomatic necrosis or pseudoprogression.